Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21992699 | 0.85 | MTNR1A (0.50) | TAS1R3TAS1R1TAS1R2HTTMTNR1A | |
| SCHEMBL21991949 | 0.85 | LDHA (0.51) | FFAR1PPARGPPARALDHAKMT2A | |
| SCHEMBL21991330 | 0.85 | NPSR1 (0.48) | FFAR1PPARGPPARAKMT2AATM | |
| SCHEMBL21991573 | 0.85 | KMT2A (0.50) | FFAR1PPARGPPARAKMT2A | |
| SCHEMBL21991878 | 0.82 | MTNR1A (0.58) | TAS1R3TAS1R1TAS1R2HTTMTNR1A | |
| SCHEMBL21991971 | 0.82 | PPARG (0.50) | FFAR1PPARGPPARAKMT2A | |
| SCHEMBL21991928 | 0.82 | NPC1 (0.46) | TAS1R3TAS1R1TAS1R2MTNR1AMTNR1B | |
| SCHEMBL21992715 | 0.81 | ALOX15 (0.45) | TAS1R3TAS1R1TAS1R2MTNR1AMTNR1B | |
| SCHEMBL21991350 | 0.81 | FNTA (0.48) | FFAR1PPARGPPARAKMT2A | |
| SCHEMBL5317085 | 0.79 | HTT (0.55) | HTTFFAR1LDHAKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | TAS1R3 1961/4885TAS1R1 1864/4885TAS1R2 2687/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | TAS1R3 1961/4885TAS1R1 1864/4885TAS1R2 2687/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | TAS1R3 1961/4885TAS1R1 1864/4885TAS1R2 2687/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | TAS1R3 1961/4885TAS1R1 1864/4885TAS1R2 2687/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | TAS1R3 1961/4885TAS1R1 1864/4885TAS1R2 2687/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | TAS1R3 1961/4885TAS1R1 1864/4885TAS1R2 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.